Boehringer med cuts bleeding risk in stroke patients

Boehringer Ingelheim's new Pradaxa blood thinner lowered the risk of major bleeding in patients taking the drug to prevent another stroke or stroke-like attack, according to a new analysis of a study. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.